Invest News DetailBloomberg - Zentiva NV, the Czech generic- drugmaker part-owned by France's Sanofi-Aventis SA, said 2007 revenue rose 19 percent because of income from its new Turkish unit. Sales climbed to about 16.7 billion koruna ($962.4 million) from 14 billion koruna in 2006, the Prague-based company said in an e-mailed statement. Zentiva's fourth-quarter revenue rose 34 percent to 5.5 billion koruna from a year earlier. The drugmaker will report full results on March 10. Zentiva acquired a 75 percent stake in the Eczacibasi Group's generic-drug making unit last year for 460 million euros ($671.2 million) in cash. Turkey contributed 2.7 billion koruna to annual sales, accounting for all of the increase from 2006.